These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11834180)

  • 21. Asthma management: curtailing costs and improving patient outcomes.
    Massanari MJ
    J Asthma; 2000 Dec; 37(8):641-51. PubMed ID: 11192228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Biological engineering for new asthma therapy].
    Van Hage M; Grönlund H; Gafvelin G
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1942-5. PubMed ID: 18681377
    [No Abstract]   [Full Text] [Related]  

  • 23. Asthma: will the therapeutic strategy change?
    Muñoz-López F
    Allergol Immunopathol (Madr); 2003; 31(4):201-4, 205-8. PubMed ID: 12890411
    [No Abstract]   [Full Text] [Related]  

  • 24. Mepolizumab (Nucala) for severe eosinophilic asthma.
    Med Lett Drugs Ther; 2016 Jan; 58(1486):11-2. PubMed ID: 26761344
    [No Abstract]   [Full Text] [Related]  

  • 25. Costs of specific immunotherapy.
    Negro Alvarez JM
    J Investig Allergol Clin Immunol; 1997; 7(5):362-3. PubMed ID: 9416548
    [No Abstract]   [Full Text] [Related]  

  • 26. [Pharmacoeconomic aspects of bronchial asthma].
    Prosekova EV; Gel'tser BI; Shestovskaia TN
    Ter Arkh; 2000; 72(3):55-8. PubMed ID: 10776656
    [No Abstract]   [Full Text] [Related]  

  • 27. [Total control of asthma].
    Pérez Martín J
    Rev Alerg Mex; 2004; 51(5):163-5. PubMed ID: 15794404
    [No Abstract]   [Full Text] [Related]  

  • 28. Costs of asthma treatment in Estonia.
    Kiivet RA; Kaur I; Lang A; Aaviksoo A; Nirk L
    Eur J Public Health; 2001 Mar; 11(1):89-92. PubMed ID: 11276578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacoeconomic considerations for allergen immunotherapy.
    Bernstein JA
    Clin Allergy Immunol; 2004; 18():151-64. PubMed ID: 15042914
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost, morbidity, and control of asthma in Hungary: The Hunair Study.
    Herjavecz I; Nagy GB; Gyurkovits K; Magyar P; Dobos K; Nagy L; Alemao E; Ben-Joseph R
    J Asthma; 2003 Sep; 40(6):673-81. PubMed ID: 14579999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uncontrolled asthma in a commercially insured population from 2002 to 2007: trends, predictors, and costs.
    Sawicki GS; Vilk Y; Schatz M; Kleinman K; Abrams A; Madden J
    J Asthma; 2010 Jun; 47(5):574-80. PubMed ID: 20560831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complexity of treatment adherence in adults with asthma: challenges and opportunities.
    Schmier JK; Leidy NK
    J Asthma; 1998; 35(6):455-72. PubMed ID: 9751063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The efficacy of specific hyposensitization in bronchial asthma and pollinosis].
    Bulakhova EK
    Vrach Delo; 1991 Feb; (2):89-91. PubMed ID: 2058136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Costs due to asthma medical care in a group of children from northeastern Mexico].
    Gallardo Martínez G; Arias Cruz A; González Díaz SN; Galindo Rodríguez G
    Rev Alerg Mex; 2007; 54(3):82-5. PubMed ID: 17849793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revisiting the cost-effectiveness of omalizumab.
    Campbell JD; Spackman DE; Sullivan SD
    Allergy; 2007 Dec; 62(12):1469. PubMed ID: 17983382
    [No Abstract]   [Full Text] [Related]  

  • 36. Reducing asthma morbidity and mortality. Cost containment strategies.
    Kowalski AF
    AAOHN J; 2000 Sep; 48(9):418-22. PubMed ID: 11760288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost effectiveness of treatment with salmeterol/fluticasone compared to montelukast for the control of persistent asthma in children].
    Rely K; McQuire SE; Alexandre PK; Escudero GS
    Value Health; 2011; 14(5 Suppl 1):S43-7. PubMed ID: 21839898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COST-effectiveness of salmeterol/fluticasone propionate combination (Advair(®)) in uncontrolled asthma in Canada.
    Ismaila AS; Risebrough N; Li C; Corriveau D; Hawkins N; FitzGerald JM; Su Z
    Respir Med; 2014 Sep; 108(9):1292-302. PubMed ID: 25175480
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diagnostics and therapy of asthma].
    Duodecim; 2000; 116(22):2568-84. PubMed ID: 12053356
    [No Abstract]   [Full Text] [Related]  

  • 40. Economic evaluation of sublingual immunotherapy: an analysis of literature.
    Ciprandi G; Agostinis F; Amoroso S; Ariano R; Barbato A; Bassi M; Cadario G; Campi P; Cardinale F; Romano C; Incorvaia C; Danneo R; Dal Bo S; Di Gioacchino M; Fiocchi A; Galimberti M; Galli E; Giovannini M; La Grutta S; Lombardi C; Marcucci F; Marseglia GL; Mastrandrea F; Minelli M; Nettis E; Novembre E; Ortolani C; Pajno G; Piras PP; Passalacqua G; Patriarca G; Pucci S; Quercia O; Romano A; Schiavino D; Sforza M; Tosca MA; Tripodi S; Zambito M; Puccinelli P; Frati F
    Eur Ann Allergy Clin Immunol; 2007; 39 Spec No():21-6. PubMed ID: 18924463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.